OncLive TV

OncLive® TV is an editorial video program featuring one-on-one live and/or virtual interviews with key opinion leaders in the oncology field for their expert insight on breaking news, regulatory updates, practice-changing data presented at medical meetings, and other pivotal topics in a cancer specialty, including breast cancer, lung cancer, genitourinary cancers, gastrointestinal cancers, gynecologic cancers, and hematologic cancers.

Dr Fisch on the Incidence of Neutropenia With Sacituzumab Govitecan in Advanced Breast Cancer

February 26th 2025

Samantha Fisch, MD, discusses rates of neutropenia in patients with advanced breast cancer treated with sacituzumab govitecan.

Dr Daneshmand on Using TAR-200 to Address Unmet Needs in BCG-Unresponsive NMIBC

February 25th 2025

Sia Daneshmand MD, discusses how the intravesical therapy TAR-200 could address unmet needs for patients with high-risk, BCG-unresponsive NMIBC with CIS.

Dr Brem on the Potential Shift Away From Chemotherapy in Follicular Lymphoma

February 25th 2025

Elizabeth A. Brem, MD, highlights upcoming changes in the follicular lymphoma treatment paradigm that could move the field beyond chemotherapy.

Dr Randall on the Utility of Intraoperative Peripheral Margin Assessment in Soft Tissue Sarcomas

February 24th 2025

R. Lor Randall, MD, FACS, discusses the utility of routine intraoperative frozen margin assessment in soft tissue sarcoma.

Dr Janjigian on 5-Year Data With Nivolumab Plus Chemotherapy in Gastric/GEJ/Esophageal Cancer

February 24th 2025

Yelena Y. Janjigian, MD, discusses 5-year follow-up findings for nivolumab plus chemotherapy vs chemotherapy alone in gastric/GEJ adenocarcinoma.

Dr Awan on Patient Characteristics Associated With CAR T-Cell Candidacy in CLL

February 24th 2025

Farrukh Awan, MD, discusses patient characteristics that confer candidacy for CAR T-cell therapy for the management of chronic lymphocytic leukemia.

Dr Garje on Clinical Outcomes With Multimodal Approaches in Invasive Primary Urethral Cancer

February 24th 2025

Rohan Garje, MD, discusses clinical outcomes among patients with invasive primary urethral cancer based on varying treatment approaches and histology.

Dr Daneshmand on Findings From the SunRISE-1 Trial of TAR-200 in BCG-Unresponsive NMIBC

February 24th 2025

Sia Daneshmand MD, discusses key efficacy findings from the SunRISE-1 trial of TAR-200 in patients with BCG-unresponsive, high-risk NMIBC with CIS.

Dr Camidge on Best Practices for Biomarker Testing in NSCLC

February 24th 2025

D. Ross Camidge, MD, PhD, discusses the benefits of biomarker testing and the potential value of longitudinal testing in non–small cell lung cancer.

Dr Patel on the Potential for Adjuvant Immunotherapy in CSCC

February 24th 2025

Sapna Patel, MD, discusses the potential for adjuvant immunotherapy in patients with high-risk cutaneous squamous cell carcinoma.

Dr Hinchcliff on the Benefits of Chemoimmunotherapy in Endometrial Cancer

February 21st 2025

Emily M. Hinchcliff, MD, MPH, discusses how the addition of immunotherapy to chemotherapy has influenced the endometrial cancer treatment paradigm.

Dr Cortese on the Role of Venetoclax in CLL Immune Synapse Repair

February 21st 2025

Matthew Cortese, MD, MPH, discusses the immunologic changes observed with venetoclax in patients with CLL.

Dr Harrison on Investigational JAK Inhibitor–Based Combinations in Myelofibrosis

February 21st 2025

Claire Harrison, MD, FRCP, FRCPath, discusses ongoing research with first-line JAK inhibitors for patients with myelofibrosis.

Dr Falchi on Long-Term Outcomes of Fixed-Duration Epcoritamab Plus R-CHOP in DLBCL

February 21st 2025

Lorenzo Falchi, MD, discusses the long-term outcomes of fixed-duration epcoritamab plus R-CHOP in previously untreated patients with DLBCL.

Dr Nathanson on Next Steps for Identifying Novel Resistance Mechanisms in Breast Cancer

February 21st 2025

Katherine L. Nathanson, MD, discusses the next steps for identifying novel mechanisms of resistance beyond reversion mutations in breast cancer.

Dr Dreyling on Safety Data With ASCT Plus Ibrutinib and Rituximab in Lower-Risk, Younger MCL

February 21st 2025

Martin Dreyling, MD, discusses updated safety results from the randomized phase 3 TRIANGLE trial in younger patients with lower-risk MCL.

Dr Fox on the Design of the TERZO Trial of Duvelisib in R/R Nodal T-Cell Lymphoma

February 20th 2025

Christopher P. Fox, PhD, MBChB(Hons), FRCP FRCPath, discusses the TERZO trial investigating duvelisib in relapsed/refractory nodal T-cell lymphoma.

Dr Hernandez-Ilizaliturri on the Implications of Immunologic Changes With Venetoclax in CLL

February 19th 2025

Francisco J. Hernandez-Ilizaliturri, MD, details the clinical implications of venetoclax for the treatment of patients with CLL regarding T-cell repair.

Dr Vachhani on the Rationale for Evaluating Navtemadlin as a Ruxolitinib Add-On in Myelofibrosis

February 18th 2025

Pankit Vachhani, MD, discusses the rationale for evaluating navtemadlin as an add-on to ruxolitinib in myelofibrosis after a suboptimal response to ruxolitinib alone.

Dr Lee on the Real-World Safety Profile of Axi-Cel in R/R LBCL

February 18th 2025

Dasom (Caroline) Lee, MD, details the safety results of second-line axicabtagene ciloleucel in real-world patients with relapsed/refractory LBCL.